Literature DB >> 33436399

DPP-4 Inhibitors and Respiratory Infection: A Systematic Review and Meta-analysis of the Cardiovascular Outcomes Trials.

Guillaume Grenet1,2, Samia Mekhaldi2, Sabine Mainbourg2,3, Marine Auffret4,2, Catherine Cornu2,5, Jean-Luc Cracowski6, François Gueyffier2, Jean-Christophe Lega2,3, Michel Cucherat4,2.   

Abstract

Entities:  

Year:  2021        PMID： 33436399     DOI： 10.2337/dc20-2018

Source DB:  PubMed          Journal:  Diabetes Care        ISSN： 0149-5992            Impact factor:   19.112


× No keyword cloud information.
  3 in total

1.  Meta-analysis of the hallmark cardiovascular and renal outcome trials addressing the risk for respiratory tract infections with sodium-glucose co-transporter-2 inhibitors: Implications for the COVID-19 pandemic.

Authors:  Dimitrios Patoulias; Christodoulos Papadopoulos; Aristi Boulmpou; Michael Doumas
Journal:  Diabetes Obes Metab       Date:  2021-03-12       Impact factor: 6.408

2.  [Executive Summary from Expert consensus on effectiveness and safety of iDPP-4 in the treatment of patients with diabetes and COVID-19].

Authors:  Francisco Javier Carrasco-Sánchez; Enrique Carretero-Anibarro; Manuel Ángel Gargallo; Ricardo Gómez-Huelgas; Juan Francisco Merino-Torres; Domingo Orozco-Beltrán; Pedro José Pines Corrales; Manuel Antonio Ruiz Quintero
Journal:  Endocrinol Diabetes Nutr       Date:  2021-11-06

3.  Is sitagliptin effective for SARS-CoV-2 infection: false or true prophecy?

Authors:  Basil Mohammed Alomair; Hayder M Al-Kuraishy; Ali K Al-Buhadily; Ali I Al-Gareeb; Michel De Waard; Engy Elekhnawy; Gaber El-Saber Batiha
Journal:  Inflammopharmacology       Date:  2022-09-30       Impact factor: 5.093
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.